MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Vaccination from Covid-19 in people with Parkinson`s disease

J. Salimjonov, N. Rashidova, K. Khalimova, R. Matmurodov (Tashkent, Uzbekistan)

Meeting: 2023 International Congress

Abstract Number: 299

Keywords: Hypokinesia, Neurospheres, Parkinson’s

Category: Parkinsonism, Others

Objective: To assess safety and efficacy of COVID-19 vaccines against SARS-CoV-2 in people with Parkinson’s disease.

Background: Different forms of vaccines have been developed to prevent the SARS-CoV-2 virus and subsequent COVID-19 disease. These vaccines can help to mitigate risk of becoming infected with SARS-CoV-2, which can lead to serious, life-threating disease to people with Parkinson’s disease.

Method: The study included patients with Parkinson’s disease

who received a full course of vaccination, including a booster dose of the

vaccine. All patients were followed up for 6 months after receiving a booster dose

of the vaccine. We collected patient data using a standard form. The form contained

questions about patient demographics, current anti-Parkinson’s drugs, and information about vaccinations and side effects.

Results: A total of 38 people with PD participated in the study. Of the 38 patients, 23 (60.5%) were male and the remaining 15 (39.5%) were female. In addition, general and local post-vaccination side effects were observed in patients. When receiving the first two doses most commonly reported adverse events were (in descending order) headache, fatigue, myalgia, fever and chills. Of the local reactions in patients, pain, redness and itching were observed at the injection site. All common and local reactions were mild and resolved within 7 days after receiving the vaccine. When receiving booster dose of vaccine after 6 month, common adverse events were headache and fatigue; local reactions were pain and redness. All common and local reactions resolved within 3 days after receiving booster dose of vaccine.

Conclusion: Several neurological complications have been reported following SARS-CoV-2 vaccination, without a clear causal relationship ever being verified, including some cases of worsening PD symptoms. In our study all common and local adverse events were transient and benign nature. Deteriorated PD symptoms and new-onset movement disorders following vaccination were not observed.

To cite this abstract in AMA style:

J. Salimjonov, N. Rashidova, K. Khalimova, R. Matmurodov. Vaccination from Covid-19 in people with Parkinson`s disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/vaccination-from-covid-19-in-people-with-parkinsons-disease/. Accessed May 16, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/vaccination-from-covid-19-in-people-with-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley